Replies to post #163942 on Biotech Values

[oc631]

I think there is enough evidence that GT1b is easier to cure (vs. GT1a), so GILD is exploiting this in the GT1b heavy Russian market.

Why wouldn't Russian regulators support Sofo/PegRiba in GT1 which will show 90+% SVR rates as opposed to Sofo/Riba which will likely be 50% +/-? Do you think Russia cares more about tolerability than efficacy? Russia's a tough-love country. I should know I'm married to a Russian and I've been there many times.